S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Massive Supercycle Investment Opportunities for 2022-2027 (Ad)pixel
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Massive Supercycle Investment Opportunities for 2022-2027 (Ad)pixel
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
Massive Supercycle Investment Opportunities for 2022-2027 (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Massive Supercycle Investment Opportunities for 2022-2027 (Ad)pixel
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Massive Supercycle Investment Opportunities for 2022-2027 (Ad)pixel
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
Massive Supercycle Investment Opportunities for 2022-2027 (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Massive Supercycle Investment Opportunities for 2022-2027 (Ad)pixel
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Massive Supercycle Investment Opportunities for 2022-2027 (Ad)pixel
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
Massive Supercycle Investment Opportunities for 2022-2027 (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Massive Supercycle Investment Opportunities for 2022-2027 (Ad)pixel
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
Massive Supercycle Investment Opportunities for 2022-2027 (Ad)pixel
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Wall Street slips as weak earnings hit tech, travel stocks
Massive Supercycle Investment Opportunities for 2022-2027 (Ad)pixel
NASDAQ:BCLI

Brainstorm Cell Therapeutics - BCLI Earnings Date, Estimates & Call Transcripts

$2.93
-0.09 (-2.98%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.83
$3.01
50-Day Range
$2.55
$3.02
52-Week Range
$2.52
$4.46
Volume
68,134 shs
Average Volume
71,225 shs
Market Capitalization
$106.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Earnings Summary

Upcoming
Earnings Date
Aug. 11Estimated
Actual EPS
(May. 16)
-$0.15 Missed By -$0.02
Consensus EPS
(May. 16)
-$0.13
Last Year's Q2 EPS
(4/25/2021)
-$0.19
Skip Charts & View Estimated and Actual Earnings Data

BCLI Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BCLI Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Brainstorm Cell Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20221($0.13)($0.13)($0.13)
Q2 20221($0.14)($0.14)($0.14)
Q3 20221($0.15)($0.15)($0.15)
Q4 20221($0.17)($0.17)($0.17)
FY 20224($0.59)($0.59)($0.59)

BCLI Earnings Date and Information

Brainstorm Cell Therapeutics last issued its quarterly earnings results on May 16th, 2022. The biotechnology company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.02. Brainstorm Cell Therapeutics has generated ($0.64) earnings per share over the last year (($0.64) diluted earnings per share). Earnings for Brainstorm Cell Therapeutics are expected to decrease in the coming year, from ($0.61) to ($0.65) per share. Brainstorm Cell Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 11th, 2022 based off prior year's report dates.

Brainstorm Cell Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/11/2022
(Estimated)
        
5/16/2022Q1 2022($0.13)($0.15)($0.02)($0.15)    
3/28/2022Q4 2021($0.20)($0.17)+$0.03($0.17)    
11/15/20219/30/2021($0.21)($0.15)+$0.06($0.15)    
8/5/20216/30/2021($0.24)($0.17)+$0.07($0.17)    
4/25/20213/31/2021($0.26)($0.19)+$0.07($0.19)  
2/3/202112/31/2020($0.48)($0.37)+$0.11($0.37)  
10/15/20209/30/2020($0.26)($0.14)+$0.12($0.14)  
8/5/20206/30/2020($0.26)($0.25)+$0.01($0.25)  
5/7/20203/31/2020($0.23)($0.32)($0.09)($0.32)  
2/18/2020Q4 2019($0.21)($0.3381)($0.1281)($0.34)  
11/14/2019Q3($0.22)($0.25)($0.03)($0.25)$1.50 million  
8/13/20196/30/2019($0.11)($0.23)($0.12)($0.23)$1.50 million
5/10/2019Q1 2019($0.06)($0.24)($0.18)($0.24)
3/29/2019Q4 2018($0.26)($0.26)($0.26)
10/29/20189/30/2018($0.10)($0.15)($0.05)($0.15)$1.50 million
7/23/2018Q2 2018($0.14)($0.16)($0.02)($0.16)$1.50 million
5/14/2018Q1 2018($0.14)($0.12)+$0.02($0.12)
3/8/2018Q4 2017($0.09)$0.02+$0.11$0.02  
10/17/2017Q3 2017($0.16)($0.13)+$0.03($0.13)
8/14/2017Q2 2017($0.10)($0.06)+$0.04($0.06)
5/15/2017Q1 2017($0.30)($0.10)+$0.20($0.10)
3/30/2017Q4 2016($0.07)($0.0330)+$0.0370($0.03)
11/14/2016Q3 2016($0.11)($0.09)+$0.02($0.09)
8/11/2016Q2($0.18)($0.05)+$0.13($0.05)
5/10/2016Q116($0.25)($0.10)+$0.15($0.10)
3/10/2016Q415($0.15)($0.07)+$0.08($0.07)
11/17/2015Q3($0.14)($0.14)($0.14)
8/13/2015Q215($0.13)($0.12)+$0.01($0.12)  
5/14/2015Q115($0.14)($0.12)+$0.02($0.12)  
3/26/2015Q414($0.18)($0.18)($0.18)
11/13/2014($0.12)($0.16)($0.04)  
11/13/2014Q3 14($0.12)($0.16)($0.04)($0.16)












Brainstorm Cell Therapeutics Earnings - Frequently Asked Questions

When is Brainstorm Cell Therapeutics's earnings date?

Brainstorm Cell Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 11th, 2022 based off last year's report dates. Learn more on BCLI's earnings history.

Did Brainstorm Cell Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Brainstorm Cell Therapeutics (NASDAQ:BCLI) missed the analysts' consensus estimate of ($0.13) by $0.02 with a reported earnings per share (EPS) of ($0.15). Learn more on analysts' earnings estimate vs. BCLI's actual earnings.

How can I listen to Brainstorm Cell Therapeutics's earnings conference call?

The conference call for Brainstorm Cell Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Brainstorm Cell Therapeutics's conference call transcript?

The conference call transcript for Brainstorm Cell Therapeutics's latest earnings report can be read online. Read Transcript

How much profit does Brainstorm Cell Therapeutics generate each year?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) has a recorded net income of -$24.46 million. BCLI has generated -$0.64 earnings per share over the last four quarters.

What is Brainstorm Cell Therapeutics's EPS forecast for next year?

Brainstorm Cell Therapeutics's earnings are expected to decrease from ($0.61) per share to ($0.65) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:BCLI) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.